There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer ...

Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating ...

The optimal therapeutic dosage is 0.5-1 mg administered ... to MAO-B inhibition, rasagiline has demonstrated neuroprotective properties in experimental laboratory models. The mechanisms whereby ...

There’s a precedent for combining the two checkpoint inhibitor mechanisms in HCC, as Bristol-Myers Squibb claimed FDA approval last month for the combination of its PD-1 drug Opdivo (nivolumab ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...